Price
Financials
Consolidated, Rs crore| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Expenses | 12 | 23 | 173 | 309 | 464 | 487 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| Other Income | 0 | 4 | 3 | 19 | 47 | 33 |
| Interest | 1 | 2 | 9 | 22 | 25 | 27 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 35 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 | 172 |
| Tax % | 13% | 32% | -31% | 17% | 24% | |
| Net Profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | 162% | 51% | ||
| Compounded Profit Growth | % | % | 139% | 87% | ||
| Stock Price CAGR | % | % | % | 103% | ||
| Return on Equity | % | 14% | 14% | 13% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 |
| Borrowings | 15 | 63 | 258 | 315 | 342 |
| Other Liabilities | 8 | 23 | 160 | 126 | 328 |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 |
| Fixed Assets | 7 | 27 | 235 | 301 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 17 |
| Investments | 15 | 16 | 0 | 0 | 4 |
| Other Assets | 29 | 53 | 289 | 754 | 827 |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing Activity | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing Activity | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/OP | -526% | 3% | -56% | -41% | 45% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | 18% | 12% | 11% | 15% |
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 45.77% | 45.78% | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% |
| FIIs | 4.25% | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% |
| DIIs | 11.77% | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% |
| Public | 38.20% | 40.39% | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% |
| No. of Shareholders | 49,518 | 37,653 | 36,389 | 34,917 | 34,401 | 34,126 | 36,498 |
Fundamentals
Market Cap₹ 6,464 Cr.
Current Price₹ 1,404
Stock P/E51.2
Book Value₹ 203
ROCE15.1 %
ROE13.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)51%
Compounded Profit Growth (TTM)87%
Consolidated figures.
Ownership
Promoter holding45.82% (+0.04 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SENORES | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +0.4% | -2.8% | +3.2 pts |
| 1 month | -7.2% | -6.8% | -0.4 pts |
| 3 months | -2.3% | -7.6% | +5.3 pts |
| 6 months | +77.7% | +0.4% | +77.3 pts |
| 1 year | +92.7% | -9.9% | +102.6 pts |
18 mutual fund schemes hold about ₹428 Cr.
Over three months 9 bought more and 4 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| HSBC Small Cap Fund | 0.37% | 71 | -16% |
| HSBC Value Fund | 0.41% | 62 | -2% |
| Mahindra Manulife Large & Mid Cap Fund | 2.10% | 62 | +3% |
| TRUSTMF Small Cap Fund | 1.44% | 41 | -9% |
| HSBC Multi Cap Fund | 0.63% | 38 | -17% |
| Bajaj Finserv Small Cap Fund | 1.09% | 29 | +2% |
| Bajaj Finserv Flexi Cap Fund | 0.29% | 24 | +52% |
| HSBC India Export Opportunities Fund | 1.27% | 17 | -25% |
| Bajaj Finserv Multi Asset Allocation Fund | 0.82% | 16 | +4% |
| Mahindra Manulife Balanced Advantage Fund | 1.40% | 13 | +8% |
| Bajaj Finserv Consumption Fund | 1.85% | 11 | +10% |
| TRUSTMF Multi Cap Fund | 1.29% | 10 | +100% |
| Bajaj Finserv Healthcare Fund | 2.15% | 9 | -4% |
| TRUSTMF Flexi Cap Fund | 0.81% | 8 | +100% |
| WOC Pharma and Healthcare Fund | 0.85% | 8 | +16% |
| TRUSTMF Mid Cap Fund | 1.40% | 6 | +83% |
| TRUSTMF Large & Mid Cap Fund | 0.83% | 3 | +100% |
| Bandhan BSE Healthcare Index Fund | 0.22% | 0 | +5% |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹180 Cr +30.4% vs Jun 2025.
Net profit ₹30 Cr +42.9%.
Against our estimate for Jun 2026: sales -18.4%, profit -29.1% big miss. Our estimate for Sep 2026: sales Rs 230 Cr, profit Rs 44 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 months
Quick answers
What is the market cap of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd (SENORES) has a market capitalisation of Rs 6,464 Cr. at the 2026-10-01 close.
What is the P/E ratio of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd trades at a P/E of 51.2 on trailing twelve-month profit, at the 2026-10-01 close.
What were Senores Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Senores Pharmaceuticals Ltd sales was Rs 180 Cr (+30.4% vs Jun 2025) and net profit was Rs 30 Cr.
What is the 52-week high and low of Senores Pharmaceuticals Ltd?
The 52-week high is Rs 1,599.00 and the 52-week low is Rs 684.60.